Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti‐A/B immunoaffinity chromatography and to a lesser extent with anti‐A donor screening
Sign Up to like & getrecommendations! Published in 2018 at "Transfusion"
DOI: 10.1111/trf.14918
Abstract: The risk of hemolytic events (HEs) with intravenous immunoglobulin (IVIG) therapy appears to be linked to isoagglutinins (anti‐A and anti‐B) in the product. Patient risk factors include high IVIG dose, blood group, and underlying inflammatory… read more here.
Keywords: intravenous immunoglobulin; risk; immunoglobulin modeling; hemolytic adverse ... See more keywords